Les données COVID-19 anonymisées reçues des États Parties par l’intermédiaire de la plateforme de données COVID-19 resteront la propriété de l’État Partie contributeur et seront utilisées par l’OMS à des fins de vérification, d’évaluation et d’assistance conformément au RSI (...2005), notamment pour éclairer la riposte de santé publique et les mesures cliniques en rapport avec la flambée épidémique de COVID-19. Pour aider à atteindre ces objectifs, l’OMS établira un groupe consultatif clinique indépendant chargé de conseiller l’OMS sur la communication et l’analyse des données COVID-19 anonymisées au niveau mondial.
more
Clinical care for severe acute respiratory infection: toolkit: COVID-19 adaptation
Centre de traitement des infections respiratoires aiguës sévères : manuel pratique pour la mise en place et la gestion d’un centre de traitement des IRAS et d’une unité de dépistage des IRAS dans les établissements de soins
El presente documento técnico tiene la finalidad de guiar el manejode cuidados intensivosde los pacientes conCOVID-19 con undoble objetivo: lograr el mejor tratamiento del paciente que contribuya a subuena evolución clínica; ygarantizar los niveles adecuados de prevención y control de la... infección para la protección de los trabajadores sanitarios y de la población en su conjunto.
more
Tại nhiều quốc gia, cú sốc của làn sóng kiểm dịch thứ nhất đã lắng xuống, số ca bệnh cũng đã giảm, việc gỡ bỏ các lệnh phong tỏa đang được xem xét hoặc đã được thực hiện ở nhiều nơi. Vũ Hán đã mở cửa trở lại. Nhưng ph...ải chăng ta đang bị đánh lừa bởi vẻ ngoài? Liệu làn sóng dịch bệnh thứ hai có xảy ra không, và nếu có thì khi nào chúng sẽ đến?
more
Cette pandémie est un défi commun pour l’ensemble de l’humanité dans l’ère de la mondialisation. À ce jour, le partage des ressources, des expériences et des leçons, qui que vous soyez, est notre seule chance de gagner. Le vrai remède à cette pandémie n’est pas l’isolement, mais... la coopération.
more
Primary care health centers and providers who care for individuals with hypertension and cardiovascular disease have an important role to play in ensuring continued access to care, reducing the risk of coronavirus infection, and appropriately managing people with these co-morbidities who acquire COV...ID-19. This guidance includes these considerations
more
As of 31 October 2020 This is the tenth edition of this summary of rapid systematic reviews, which includes the results of a rapid systematic review of currently available literature. More than 200 therapeutic options or their combinations are being investigated in more than 1,700 clinical trials. I...n this review, 46 therapeutic options are examined. The Pan American Health Organization (PAHO) is continually monitoring ongoing research on any possible therapeutic options. As evidence emerges, then PAHO will immediately assess and update its position, and particularly as it applies to any special sub-group populations such as children, expectant mothers, those with immune conditions, etc.
more
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV‑2) causing coronavirus disease 2019 (COVID-19) has reached pandemic levels;
Patients with cardiovascular (CV) risk factors and established cardiovascular disease (CVD) represent a vulnerable population when suffering from COVID-19;
Patien...ts with cardiac injury in the context of COVID-19 have an increased risk of morbidity and mortality
more
Orientação provisória 17 de março de 2020
Esta orientação rápida destina-se a profissionais de saúde pública e de prevenção e controle de infecção (PCI), gestores e profissionais de saúde, ao abordar questões relacionadas ao atendimento domiciliar de pacientes com suspeita de infecç...ão pelo nCoV que apresentem sintomas leves e o tratamento de contatos assintomáticos.
more
Medizinische KlinikIntensivmedizin und Notfallmedizin
https://doi.org/10.1007/s00063-020-00674-3
23 April 2020EMA/202483/2020 Rev
Chloroquine and hydroxychloroquine are known to potentially cause heart rhythm problems, and these could be exacerbated if treatment is combined with other medicines, such as the antibiotic azithromycin, that have similar effects on the heart.
El 31 de diciembrede 2019 las Autoridades de la República Popular China, comunicaron a la OMS varios casos de neumonía de etiología desconocida en Wuhan, una ciudad situada en la provincia china de Hubei. Una semana más tarde confirmaron que se trataba de un nuevo co...ronavirus que ha sido denominado SARS-CoV-2. Al igual que otros de la familia de los coronavirus, este virus causa diversas manifestaciones clínicas englobadas bajoel término COVID-19, que incluyen cuadros respiratorios que varían desde el resfriado común hastacuadros de neumonía grave con síndrome de distrés respiratorio, shock séptico y fallo multi-orgánico. La mayoría de los casos de COVID-19 notificados hasta el momento debutan con cuadros leves.Un punto de detección importante de casos de COVID-19es la urgencia hospitalaria. El triaje tiene como objetivo identificar y priorizar al paciente más grave. Al tratarse deuna enfermedad transmisiblese debenextremar las medidas deprecaución.
more
Centro de tratamiento de infecciones respiratorias agudas graves: manual práctico para instalar y gestionar un centro de tratamiento de las infecciones respiratorias agudas graves y una zona para el tamizaje de estas en los establecimientos de asistencia médica
Recomendações provisórias, versão 1 (13 de abril de 2020)
Oferecer recomendações sobre os cuidados iniciais de pessoas com infecção respiratória aguda (IRA) no contexto da doença do coronavírus (COVID-19), em estabelecimentos de saúde, com base no fluxograma do processo de tomada de dec...isão. Essas recomendações são preliminares e sujeitas à revisão, à medida que novas evidências estejam disponíveis. As recomendações dadas neste documento se aplicam a adultos com mais de 18 anos
more
Short Guide on the management of patients with COVID-19
A Spanish-translated clinical algorithm for management of suspected SARS-CoV-2 infection in pregnant women
Published:April 09, 2020DOI:https://doi.org/10.1016/S1473-3099(20)30285-1
The Lancet Infectious Diseases